Liposomal doxorubicin is named as a drug or biological intervention in 6 clinical trials in our China, UK, USA, Ireland and India trial registers, 3 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (3), Tianjin Medical University Cancer Institute and Hospital (1) and Sichuan Baili Pharmaceutical Co., Ltd. (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Breast Neoplasms; Undifferentiated Pleomorphic Sarcoma (UPS); Epithelial Ovarian Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Neoplasms | 3 |
| Undifferentiated Pleomorphic Sarcoma (UPS) | 1 |
| Epithelial Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Primary Peritoneal Cancer | 1 |
| Soft Tissue Sarcomas | 1 |
| Angiosarcoma | 1 |
| Fibrosarcoma | 1 |
| Leiomyosarcoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Fudan University | 1 |
| Register | Liposomal doxorubicin trials |
|---|---|
| Clinical trials in China | 5 |
| Clinical trials in UK | 3 |
| Clinical trials in USA | 3 |
| Clinical trials in Ireland | 2 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Liposomal doxorubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Liposomal doxorubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.